TP53 and cancer: As discussed above, although Wang et al. provided extensive evidence that the deletion of mutant p53 had no effect in cancer cell lines [13], a re-analysis of their data obtained with organoid-derived tumors (Figure 1) may actually support the notion that targeting mutant p53 in patients’ tumors might be a valid therapeutic strategy.